NCT07357298招募中3 期
Phase III Trial of Brain MRI Surveillance in Stage IV Breast Cancer
适应症
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 156
- 试验地点
- 2
研究概览
简要总结
This randomized, multi-institutional phase III trial evaluates whether routine surveillance brain MRI every 6 months improves detection and treatment characteristics of brain metastases in neurologically asymptomatic patients with stage IV breast cancer. Patients are stratified by receptor subtype, age, prior therapy, and study site, then randomized 1:1 to either scheduled surveillance MRIs or standard-of-care symptom-triggered imaging. The study aims to determine whether earlier detection leads to differences in treatment modality, frequency of brain metastases, leptomeningeal disease incidence, quality of life, and survival outcomes.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Screening
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologic diagnosis of breast cancer with documentation of ER/PR/HER2 status
- •Radiographic evidence of stage IV extracranial disease enrolled within 60 days of diagnosis or starting first line therapy. HR+/HER2- patients may be enrolled within 60 days of starting 2nd line therapy as well.
- •HR+ will be defined as ER and/or PR > 10%. To be classified as HER2+ disease, overexpression of HER2 by either IHC or in-situ hybridization is necessary as defined by the ASCO / CAP Guidelines
- •Triple negative will be classified as ER and PR <10% and HER2-.
- •Life expectancy ≥ 6 months
- •Eastern Cooperative Oncology Group performance status ≤ 2
- •Patients must be able to understand and the willingness to sign an informed consent for study procedures
- •Stated willingness to comply with all study procedures and availability for the duration of the study
排除标准
- •Prior diagnosis or treatment of brain metastases or leptomeningeal disease
- •History of other non-breast malignancy requiring treatment with the exception of those with a negligible risk of metastasis or death (e.g., 5-year OS of > 90%), such as but not limited to, non-melanoma skin cancers, stage I endometrioid uterine cancer, and others at the discretion of the PI
- •Neurologic symptoms warranting standard screening brain MRI in the judgement of the treating physician at time of enrollment
- •Indications warranting brain MRI for other neurologic conditions at time of study entry (including multiple sclerosis, stroke, traumatic brain injuries, epilepsy, hydrocephalus and pituitary gland disorders)
- •Contraindication towards MRI with contrast
- •Chronic kidney disease stage IV or V or end stage renal disease (CrCl <30 ml/min)
研究者
研究点 (2)
Loading locations...
相似试验
尚未招募
4 期
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)EmphysemaNCT07326592CSL Behring270
招募中
2 期
Efficacy, Safety, and Pharmacokinetics of LP-003 Injection in Allergic Asthma PatientsAllergic AsthmaNCT07342803Longbio Pharma200
尚未招募
2 期
Phase II/III Randomized Trial of UC-MSC Secretome vs Sodium Hyaluronate in Knee OsteoarthritisNCT07337863Universitas Sriwijaya50
招募中
3 期
Efficacy and Safety of BV100 Plus Low Dose Polymyxin B Versus Colistin Plus High-dose Ampicillin/Sulbactam in Patients With Hospital-acquired or Ventilator-associated Bacterial Pneumonia Due to Carbapenem-resistant Acinetobacter Baumannii-calcoaceticus ComplexVentilator Associated Bacterial Pneumonia (VABP)Colistin Resistanrt ABCAcinetobacter Baumannii-calcoaceticus ComplexNCT07326540BioVersys SAS248
招募中
3 期
A study to evaluate the efficacy and safety of Clascoterone solution in treatment of male pattern hair loss.Androgenetic Alopecia2023-504421-39-00Cassiopea S.p.A.629